Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 3Gliosarcoma 2Stomach Neoplasms 1Sarcoma 1Neuroblastoma 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Hematologic Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 6Radiosurgery 6Nivolumab 6Magnetic Resonance Spectroscopy 6Ifosfamide 5Bevacizumab 5cabozantinib 4Sunitinib 4Sirolimus 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Carboplatin 4Specimen Handling 3Sorafenib 3Paclitaxel 3Melphalan 3Ipilimumab 3Cyclophosphamide 3Busulfan 3temsirolimus 2lenvatinib 2etoposide phosphate 2cediranib 2belzutifan 2alectinib 2Trastuzumab 2Thiotepa 2Stem Cell Transplantation 2Radiotherapy 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × capmatinib × CNS × Clear all
NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡